New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
10:08 EDTIMMUImmunomedics provides update on subcutaneous injections of Veltuzumab
Immunomedics announced that subcutaneous administration of veltuzumab, as a single agent, demonstrated promising activity in patients with relapsed immune thrombocytopenia, even in more heavily treated patients with the chronic disease, and in patients with chronic lymphocytic leukemia. In a published study, veltuzumab reversed life threatening anemia and thrombocytopenia in a patient with systemic lupus erythematosus who was unresponsive to rituximab. In non-Hodgkin lymphoma patients who had received prior therapies, 4 once-weekly infusions of veltuzumab produced a complete response rate of 25% in a study of 84 patients, even at the low dose of 80 mg/m2 given intravenously.
News For IMMU From The Last 14 Days
Check below for free stories on IMMU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
06:15 EDTIMMUImmunomedics files $130M mixed securities shelf
Subscribe for More Information
September 12, 2014
12:20 EDTIMMUImmunomedics management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use